Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadolol for Smoking Cessation in Chronic Cough
NCT01825122Phase 2Completed
- Sponsor
- Invion Limited
- Start
- Mar 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nicotine dependence comparing Placebo with Active, nadolol (2 arms). Primary endpoint: Change From Baseline in the Average Number of Cigarettes Smoked Per Day at 15 weeks. Started Mar 2014; status: completed.
02
Drugs
nadolol
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT01825122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01825122.